A significant decrease in Nf-L concentrations over the two-year treatment period and an association between higher Nf-L levels and increased relapse rate highlight its potential as a responsive biomarker of neuroaxonal damage, disease activity, and therapeutic efficacy in MS. Here, NFASC is linked to myeloid sarcoma.